Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 1/2017

01-03-2017

Current therapeutic approaches in the management of hyperglycemia in chronic renal disease

Authors: Vishnu Garla, Licy Yanes-Cardozo, Lillian F. Lien

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 1/2017

Login to get access

Abstract

Diabetes mellitus (DM) and chronic kidney disease (CKD) are intricately intertwined. DM is the most common cause of CKD. Adequate control of DM is necessary for prevention of progression of CKD, while careful management of the metabolic abnormalities in CKD will assist in achieving better control of DM. Two of the key organs involved in glucose production are the kidney and the liver. Furthermore, the kidney also plays a role in glucose filtration and reabsorption. In CKD, monitoring of glycemic control using traditional methods such as Hemoglobin A1c (Hba1c) must be done with caution secondary to associated hematological abnormalities in CKD. With regard to medication management in the care of patients with DM, CKD has significant effects. For example, the dosages of oral and non-insulin anti-hyperglycemic agents often need to be modified according to renal function. Insulin metabolism is altered in CKD, and a reduction in insulin dose is almost always needed. Dialysis also affects various aspects of glucose homeostasis, necessitating appropriate changes in therapy. Due to the aforementioned factors glycemic management in patients with DM and CKD can be quiet challenging.
Literature
1.
Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–35.CrossRefPubMed
2.
3.
Powers A. Diabetes mellitus in: Fauci a, Kasper D, Longo D, Braunwald E, Hauser S, Jameson J, Loscalzo J, editors Harrisons Princples of internal medicine. McGraw Hill, New York. 2017. pp 2275.
4.
American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care In: Diabetes - 2016. Diabetes Care 2016. 39(Suppl. 1):S13–S2.
5.
Jagannathan R, Sevick MA, Li H, Fink D, Dankner R, Chetrit A, Roth J, Bergman M. Elevated 1-hour plasma glucose levels are associated with dysglycemia, impaired beta-cell function, and insulin sensitivity: a pilot study from a real world health care setting. Endocrine. 2016;52(1):172–5.CrossRefPubMed
6.
Bergman M, Chetrit A, Roth J, Jagannathan R, Sevick M, Dankner R. One-hour post-load plasma glucose level during the OGTT predicts dysglycemia: observations from the 24year follow-up of the Israel study of glucose intolerance, obesity and hypertension. Diabetes Res Clin Pract. 2016;120:221–8.CrossRefPubMed
7.
8.
9.
10.
Mather A, Pollock C. Glucose handling by the kidney. Kidney Int. 2011;79(Suppl 120):S1–6.CrossRef
11.
Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–42.CrossRefPubMedPubMedCentral
12.
Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24(2):382–91.CrossRefPubMed
13.
Joseph SE, Heaton N, Potter D, Pernet A, Umpleby MA, Amiel SA. Renal glucose production compensates for the liver during the anhepatic phase of liver transplantation. Diabetes. 2000;49(3):450–6.CrossRefPubMed
14.
Meyer C, Stumvoll M, Dostou J, Welle S, Haymond M, Gerich J. Renal substrate exchange and gluconeogenesis in normal postabsorptive humans. Am J Physiol Endocrinol Metab. 2002;282(2):E428–34.CrossRefPubMed
15.
Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab. 2004;287(6):E1049–56.CrossRefPubMed
16.
Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165–71.CrossRefPubMed
17.
Freitas HS, Anhê GF, Melo KF, et al. Na (+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology. 2008;149:717–24.CrossRefPubMed
18.
Zhang Y, Thai K, Kepecs DM, Gilbert RE. Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease progression in the rat remnant kidney model of chronic kidney disease. PLoS One. 2016;11(1):e0144640.
19.
Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998;19(5):608–24.PubMed
20.
Alsahli M, Gerich JE. Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc. 2014;89(11):1564–71.CrossRefPubMed
21.
Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014;27(2):135–45.CrossRefPubMedPubMedCentral
22.
Garg R, Williams ME. Diabetes management in the kidney patient. Med Clin North Am. 2013;97(1):135–56.CrossRefPubMed
23.
Souto G, Donapetry C, Calviño J, Adeva MM. Metabolic acidosis-induced insulin resistance and cardiovascular risk. Metab Syndr Relat Disord. 2011;9(4):247–53.CrossRefPubMedPubMedCentral
24.
Akmal M, Massry SG, Goldstein DA, Fanti P, Weisz A, DeFronzo RA. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest. 1985;75(3):1037–44.CrossRefPubMedPubMedCentral
25.
Park J, Lertdumrongluk P, Molnar MZ, Kovesdy CP, Kalantar-Zadeh K. Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon. Curr Diab Rep. 2012;12(4):432–9.CrossRefPubMed
26.
Anastasilakis AD, Efstathiadou Z, Plevraki E, Koukoulis GN, Slavakis A, Kita M, Avramidis A. Effect of exogenous intermittent recombinant human PTH 1-34 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity. Horm Metab Res. 2008;40(10):702–7.CrossRefPubMed
27.
Mak RH, Bettinelli A, Turner C, Haycock GB, Chantler C. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab. 1985;60(2):229–33.CrossRefPubMed
28.
Massry SG. Sequence of cellular events in pancreatic islets leading to impaired insulin secretion in chronic kidney disease. J Ren Nutr. 2011;21(1):92–9.CrossRefPubMed
29.
Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42(5):864–81.CrossRefPubMed
30.
Williams ME, Garg R. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis. 2014;63(2 Suppl 2):S22–38.CrossRefPubMed
31.
Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis. 2004;44(4):715–9.CrossRefPubMed
32.
Chen HS, Wu TE, Lin HD, et al. Hemoglobin A(1c)and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis. 2010;55(5):867–74.CrossRefPubMed
33.
Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, Holmes YR, Cohen RM. Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes. 2008;57(9):2445–52.CrossRefPubMedPubMedCentral
34.
Lu JM, Ji LN, Li YF, Li QM, Lin SS, Lv XF, Wang L, Xu Y, Guo XH, Guo QY, Ma L, Du J, Chen YL, Zhao CL, Zhang QL, She QM, Jiao XM, Lu MH, Pan RQ, Gao Y. Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: a multicenter, prospective study. J Diabetes Complicat. 2016;30(8):1609–13.CrossRefPubMed
35.
Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, Calles-Escandon J, Russell GB, Freedman BI. Comparison of glycated albumin and hemoglobin a(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008;73(9):1062–8.CrossRefPubMed
36.
Freedman BI, Shenoy RN, Planer JA, Clay KD, Shihabi ZK, Burkart JM, Cardona CY, Andries L, Peacock TP, Sabio H, Byers JR, Russell GB, Bleyer AJ. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int. 2010;30(1):72–9.CrossRefPubMed
37.
Murea M, Moran T, Russell GB, Shihabi ZK, Byers JR, Andries L, Bleyer AJ, Freedman BI. Glycated albumin, not hemoglobin A1c, predicts cardiovascular hospitalization and length of stay in diabetic patients on dialysis. Am J Nephrol. 2012;36(5):488–96.CrossRefPubMed
38.
National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–86.CrossRef
39.
American Diabetes Association. Glycemic targets. Sec. 6. In Standards of Medical Care in Diabetesd 2015. Diabetes Care 2015; 38 (Suppl. 1):S33–S40.
40.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK prospective diabetes study (UKPDS) group. Lancet. 1998;352:837–53.CrossRef
41.
de Boer IH, Sun W, Cleary PA, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366–76.CrossRefPubMed
42.
Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171:1920–7.CrossRefPubMed
43.
Ramirez SP, McCullough KP, Thumma JR, et al. Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the dialysis outcomes and practice patterns study (DOPPS). Diabetes Care. 2012;35:2527–32.CrossRefPubMedPubMedCentral
44.
Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY, Wanner C, Kasiske BL, Wheeler DC, de Zeeuw D, Mogensen CE. Diabetic kidney disease: a clinical update from kidney disease: improving global outcomes. Kidney Int. 2015;87(1):20–30.CrossRefPubMed
45.
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, RA DF, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Henry RR, Hirsch IB, Jellinger PS, JB MG, Mechanick JI, Rosenblit PD, Umpierrez GE, American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE). Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm--2016 executive summary. Endocr Pract. 2016;22(1):84–113.CrossRefPubMed
46.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes. Diabetologia. 2015;58(3):429–42.CrossRefPubMed
47.
Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;1:CD002967.
48.
49.
Chan SP, Colagiuri S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract. 2015;110(1):75–81.CrossRefPubMed
50.
Rowell J, Nair L, Cox M. Non-insulin antidiabetic medications in the inpatient setting. In: Glycemic control in the hospitalized patient. Lien L, Cox M, Feinglos M, Corsino L, editors. Springer, New York; 2011. p 77–89.
51.
McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2000;36(2):133–8.CrossRefPubMed
52.
Adabala M, Jhaveri KD, Gitman M. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol Dial Transplant. 2010;25(10):3439–42.CrossRefPubMed
53.
Scholz GH, Fleischmann H. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Ther Adv Endocrinol Metab. 2014;5(5):95–123.CrossRefPubMedPubMedCentral
54.
Leiter LA, Carr MC, Stewart M, Jones-Leone A, Scott R, Yang F, Handelsman Y. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37(10):2723–30.CrossRefPubMed
55.
Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, Bosch-Traberg H, Syrén A, Umpierrez GE. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222–30.PubMed
56.
Ferrer-Garcia JC, Martinez-Chanza N, Tolosa-Torréns M, Sánchez-Juan C. Exenatide and renal failure. Diabet Med. 2010;27(6):728–9.CrossRefPubMed
57.
Hahr A, Molitch M. Management of diabetes mellitus in patients with chronic kidney disease. Clin Diabetes Endocrinol. 2015;1:2.CrossRef
58.
Fujii Y, Abe M, Higuchi T, Mizuno M, Suzuki H, Matsumoto S, Ito M, Maruyama N, Okada K, Soma M. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Expert Opin Pharmacother. 2013;14(3):259–67.CrossRefPubMed
59.
McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, Woerle HJ. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36(2):237–44.CrossRefPubMedPubMedCentral
60.
Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-Nilsson I, Schützer KM. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230–9.CrossRefPubMed
61.
Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10(7):545–55.CrossRefPubMed
62.
Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab. 2012;14(11):1032–9.CrossRefPubMed
63.
Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IVinhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340:248–55.CrossRefPubMed
64.
Ramirez SP, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, Young EW, Bailie GR, Pisoni RL, Port FK. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol. 2009;20(5):1094–101.CrossRefPubMedPubMedCentral
65.
Galle J, Kleophas W, Dellanna F, Schmid VH, Forkel C, Dikta G, Krajewski V, Fuchs W, Forst T, Pfützner A. Comparison of the effects of pioglitazone versus placebo when given in addition to standard insulin treatment in patients with type 2 diabetes mellitus requiring hemodialysis: results from the PIOren study. Nephron Extra. 2012;2(1):104–14.CrossRefPubMedPubMedCentral
66.
67.
Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011;12(1):57–69.CrossRefPubMed
68.
Bahar A, Kashi Z, Daneshpour E, Akha O, Ala S. Effects of cabergoline on blood glucose levels in type 2 diabetic patients: a double-blind controlled clinical trial. Medicine (Baltimore). 2016;95(40):e4818.CrossRef
69.
Ruiz-Herrera X, de Los Ríos EA, Díaz JM, Lerma-Alvarado RM, de la Escalera LM, López-Barrera F, Lemini M, Arnold E, de la Escalera GM, Clapp C, Macotela Y. Prolactin promotes adipose tissue fitness and insulin sensitivity in obese males. Endocrinology. 2016;2:en20161444.
70.
Kao CC, Wu PC, Wu CH, Chen LK, Chen HH, Wu MS, Wu VC. Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients. Sci Rep. 2016;11(6):18996.CrossRef
71.
Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010;12(5):384–92.CrossRefPubMedPubMedCentral
72.
Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. Cochrane database Syst Rev. 2012;12(12):CD009361.PubMed
73.
Rave K, Heise T, Pfutzner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24:886–90.CrossRefPubMed
74.
Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013;4(4):113–21.CrossRefPubMedPubMedCentral
75.
Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53(2):175–83.CrossRefPubMed
76.
Barnard K, Batch B, Lien L. Subcutaneous insulin: a guide for dosing regimens in the hospital. In: Glycemic Control in the Hospitalized patient. Lien L, Cox M, Feinglos M, Corsino L, editors. Springer, New York; 2011. pp 7–16.
77.
Trifirò G, Parrino F, Pizzimenti V, Giorgianni F, Sultana J, Muscianisi M, Troncone C, Tari DU, Arcoraci V, Santoro D, Russo G, Lacava V, Caputi AP. The management of diabetes mellitus in patients with chronic kidney disease: a population-based study in southern Italy. Clin Drug Investig. 2016;36(3):203–12.CrossRefPubMed
78.
Lien LF. Answering the challenge: Prevention of inpatient hypoglycemia. Endocr Pract. 2016;22(12):1456–8.
79.
Apel J, Reutrakul S, Baldwin D. Hypoglycemia in the treatment of hyperkalemia with insulin in patients with end-stage renal disease. Clin Kidney J. 2014;7(3):248–50.CrossRefPubMedPubMedCentral
80.
Baldwin D, Zander J, Munoz C, Raghu P, DeLange-Hudec S, Lee H, Emanuele MA, Glossop V, Smallwood K, Molitch M. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35(10):1970–4.CrossRefPubMedPubMedCentral
81.
American Diabetes Association. Glycemic targets. Sec. 6. In Standards of Medical Care in Diabetesd2015. Diabetes Care. 2015;38(Suppl. 1):S33–40.CrossRef
82.
Kreider KE, Lien LF. Transitioning safely from intravenous to subcutaneous insulin. Curr Diab Rep. 2015;15(5):23.CrossRefPubMed
83.
De Block CE, Rogiers P, Jorens PG, Schepens T, Scuffi C, Van Gaal LF. A comparison of two insulin infusion protocols in the medical intensive care unit by continuous glucose monitoring. Ann Intensive Care. 2016;6(1):115.CrossRefPubMedPubMedCentral
84.
Friedman JE, Dohm GL, Elton CW, Rovira A, Chen JJ, Leggett-Frazier N, Atkinson Jr SM, Thomas FT, Long SD, Caro JF. Muscle insulin resistance in uremic humans: glucose transport, glucose transporters, and insulin receptors. Am J Phys. 1991;261(1 Pt 1):E87–94.
85.
Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–1801. Review. Erratum in: J Clin Invest. 2006;116(8):2308.
86.
Jamaludin UK, Docherty PD, Chase JG, Shaw GM. Impact of haemodialysis on insulin sensitivity of acute renal failure (ARF) patients with sepsis in critical care. Conf Proc IEEE Eng Med Biol Soc. 2013;2013:3503–6.PubMed
87.
Abe M, Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015;11(5):302–13.CrossRefPubMed
88.
89.
Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30(5):1049–55.CrossRefPubMed
90.
91.
Paniagua R, Ventura MD, Avila-Díaz M, Cisneros A, Vicenté-Martínez M, Furlong MD, García-González Z, Villanueva D, Orihuela O, Prado-Uribe MD, Alcántara G, Amato D. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int. 2009;29(4):422–32.PubMed
92.
Canbakan M, Sahin GM. Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients. Ren Fail. 2007;29(3):289–93.CrossRefPubMed
93.
94.
Oei E, Samad N, Visser A, Chowdhury TA, Fan SL. Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia. Diabet Med. 2016;33(9):e17–20.CrossRefPubMed
95.
Apel J, Baldwin D. Improving the safety and effectiveness of insulin therapy in hospitalized patients with diabetes and chronic renal failure. Chapter 14. In: Draznin B, editor. Managing diabetes and hyperglycemia in the hospital setting – A Clinician’s Guide. Alexandria: American Diabetes Association; 2016. pp. 182–190.
96.
Selgas R, Diez JJ, Muñoz J, Miranda B, de Alvaro F, Rodriguez JC. Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study. Adv Perit Dial. 1989;5:181–4.PubMed
97.
Cryer P. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin N Am. 2010;39:641–54.CrossRef
98.
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R, American Diabetes Association, Endocrine Society. Hypoglycemia and diabetes: a report of a workgroup of the American diabetes association and the endocrine society. J Clin Endocrinol Metab. 2013;98(5):1845–59.CrossRefPubMed
99.
Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, Applegate WB, Puntakee Z, Yale JF, Cushman WC, ACCORD Study Group. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015;87(3):649–59.CrossRefPubMed
100.
UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140–7.CrossRef
101.
Reno CM, Litvin M, Clark AL, Fisher SJ. Defective counterregulation and hypoglycemia unawareness in diabetes: Mechanisms and emerging treatments. Endocrinol Metab Clin North Am. 2013;42(1):15–38.CrossRefPubMed
102.
Gosmanov AR, Gosmanova EO, Kovesdy CP. Evaluation and management of diabeticand non-diabetic hypoglycemia in end-stage renal disease. Nephrol Dial Transplant. 2016;31(1):8–15.CrossRefPubMed
103.
Horigan G, Davies M, Findlay-White F, Chaney D, Coates V. Reasons why patients referred to diabetes education programmes choose not to attend: a systematic review. Diabet Med. 2017;34(1):14–26.CrossRefPubMed
104.
Mabrey M, Cox ME, Lien LF. Hypoglycemia. In: Glycemic control in the hospitalized patient. Lien L, Cox M, Feinglos M, Corsino L, editors. Springer: New York; p. 2011
Metadata
Title
Current therapeutic approaches in the management of hyperglycemia in chronic renal disease
Authors
Vishnu Garla
Licy Yanes-Cardozo
Lillian F. Lien
Publication date
01-03-2017
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 1/2017
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-017-9416-1

Other articles of this Issue 1/2017

Reviews in Endocrine and Metabolic Disorders 1/2017 Go to the issue

ReviewPaper

Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy

ReviewPaper

Gonadal dysfunction in chronic kidney disease

ReviewPaper

Updates in hyperkalemia: Outcomes and therapeutic strategies

ReviewPaper

Hyponatremia and bone disease

ReviewPaper

Dyslipidemia in patients with chronic kidney disease

ReviewPaper

Clinical aspects of changes in water and sodium homeostasis in the elderly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits